MoonLake Immunotherapeutics develops medicines for immunologic diseases, including inflammatory skin and joint diseases. It focuses on enhancing its novel tri-specific Nanobody Sonelokimab (SLK) product, an inhibitor to treat multiple inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F. The company is conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, and radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
Name / Ticker | Price | Zen Rating |
---|---|---|
$2.58 | A | |
$8.46 | A | |
$126.40 | A |